title: Vemurafenib in leptomeningeal carcinomatosis from melanoma: a case report of near-complete response and prolonged survival.
abstract: Targeted therapies such as the BRAF inhibitors vemurafenib and dabrafenib are highly effective in the treatment of systemic metastatic melanoma and have been shown to be effective in controlling solid brain metastases; however, limited data exist on their activity in leptomeningeal spread. Here, we present a case of a 60-year-old woman who developed leptomeningeal carcinomatosis from melanoma after resection and stereotactic radiotherapy of melanoma brain metastases, with poor performance status, who received vemurafenib as first-line treatment, resulting in significant clinical and imaging response as well as prolonged survival.
authors.affiliation: aDepartment of Internal Medicine, Maimonides Medical Center bDivision of Hematology and Oncology, Maimonides Cancer Center, Brooklyn, New York, USA.
authors.forename: Charalampos S
authors.initials: CS
authors.lastname: Floudas
authors.forename: Abhinav B
authors.initials: AB
authors.lastname: Chandra
authors.forename: Yiqing
authors.initials: Y
authors.lastname: Xu
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D008545:Melanoma / Q000150:complications* / Q000473:pathology; D055756:Meningeal Carcinomatosis / Q000209:etiology* / Q000401:mortality; D008875:Middle Aged; D012189:Retrospective Studies; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016019:Survival Analysis; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib